This is consistent with findings from an ongoing multicenter phase Ia FCN-437c monotherapy study in China that is enrolling women with HR+/HER2– advanced breast cancer (NCT04488107) [25], as well as single-agent data reported for approved CDK4/6 inhibitors [29,34,35]. The gene discussed is HR; the disease is breast carcinoma.